N
EDIT icon

Natixis’s Editas Medicine EDIT Stock Holding History

Natixis’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-120,609
Closed -$1.22M – 1059
2023
Q4 		$1.22M Buy
+120,609
New +$1.06M 0.01% 491
2023
Q3 		– Sell
-2,623
Closed -$21.6K – 1021
2023
Q2 		$21.6K Sell
2,623
-43
-2% -$375 ﹤0.01% 889
2023
Q1 		$19.3K Hold
2,666
– – ﹤0.01% 869
2022
Q4 		$23.6K Buy
+2,666
New +$29.3K ﹤0.01% 972
2022
Q2 		– Sell
-84,666
Closed -$1.61M – 1210
2022
Q1 		$1.61M Sell
84,666
-127
-0.1% -$2.36K 0.01% 796
2021
Q4 		$2.25M Hold
84,793
– – 0.01% 743
2021
Q3 		$3.48M Sell
84,793
-8,366
-9% -$458K 0.01% 617
2021
Q2 		$5.28M Sell
93,159
-10,728
-10% -$396K 0.02% 371
2021
Q1 		$4.36M Buy
+103,887
New +$5.92M 0.01% 541

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Natixis's EDIT Position: Q1 2024 in Review

Natixis sold out of Editas Medicine (EDIT) in Q1 2024, closing a stake of 120,609 shares — an estimated $1.22M sold.

Natixis first reported a position in EDIT in Q1 2021 and held it in 9 quarters. The position peaked at $5.28M in Q2 2021. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.

  • Natixis reported no remaining Editas Medicine position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 120,609 Editas Medicine shares in Q1 2024, an estimated $1.22M.
  • Natixis first reported a position in Editas Medicine in Q1 2021 and held it in 9 quarters.
  • Natixis's Editas Medicine position peaked at $5.28M in Q2 2021.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.